Capabilities for Advanced Injectables Development ......Expansion of Evonik Vancouver Laboratories...
4
SUBSCRIPTIONS SUBSCRIPTIONS CURRENT/BACK ISSUES CURRENT/BACK ISSUES MARKET NEWS & TRENDS MARKET NEWS & TRENDS EXECUTIVE INTERVIEWS EXECUTIVE INTERVIEWS SEARCH ANALYTICAL/TESTING ANALYTICAL/TESTING BIOAVAILABILITY BIOAVAILABILITY & SOLUBILITY & SOLUBILITY BIO BIO PLATFORMS PLATFORMS DRUG DRUG DELIVERY DELIVERY DEVICES DEVICES EXCIPIENTS EXCIPIENTS FORMULATION FORMULATION DEVELOPMENT DEVELOPMENT CONTRACT CONTRACT SERVICES SERVICES Evonik Expands North American Contract Evonik Expands North American Contract Development & Manufacturing Development & Manufacturing Capabilities for Advanced Injectables Capabilities for Advanced Injectables Evonik recently announced a €35 million expansion of Evonik recently announced a €35 million expansion of its contract development and manufacturing (CDMO) its contract development and manufacturing (CDMO) capabilities in North America to meet growing demand capabilities in North America to meet growing demand for controlled release injectable formulations. The for controlled release injectable formulations. The expansion of the U.S. and Canadian facilities, which expansion of the U.S. and Canadian facilities, which includes the installation of a new lling line, production includes the installation of a new lling line, production facilities and analytical labs, will create more than 50 facilities and analytical labs, will create more than 50 jobs. jobs. “Evonik is a global strategic partner to pharmaceutical “Evonik is a global strategic partner to pharmaceutical companies seeking enabling solutions for polymer and companies seeking enabling solutions for polymer and liposome-based dosage forms,” said Don Enns, Global liposome-based dosage forms,” said Don Enns, Global Head of Drug Delivery for the Evonik Health Care Head of Drug Delivery for the Evonik Health Care Business Line. “By increasing the production capacity of Business Line. “By increasing the production capacity of our RESOMER our RESOMER functional excipients and expanding our functional excipients and expanding our contract development and production services, we can contract development and production services, we can further help customers transform their APIs into high- further help customers transform their APIs into high- performance parenteral medicines.” performance parenteral medicines.” Expansion of Evonik Birmingham Laboratories Expansion of Evonik Birmingham Laboratories Evonik Birmingham Laboratories (BHM) in the U.S. State Evonik Birmingham Laboratories (BHM) in the U.S. State of Alabama is a global centre of excellence for of Alabama is a global centre of excellence for biomaterials and polymer-based injectable dosage biomaterials and polymer-based injectable dosage forms. forms. Contract Services, Contract Services, Exclusive Online Content, Exclusive Online Content, Formulation Development Formulation Development ®
Transcript of Capabilities for Advanced Injectables Development ......Expansion of Evonik Vancouver Laboratories...
SUBSCRIPTIONSSUBSCRIPTIONSCURRENT/BACK ISSUESCURRENT/BACK ISSUESMARKET NEWS & TRENDSMARKET NEWS & TRENDSEXECUTIVE INTERVIEWSEXECUTIVE INTERVIEWS
SEARCH
ANALYTICAL/TESTINGANALYTICAL/TESTINGBIOAVAILABILITYBIOAVAILABILITY& SOLUBILITY& SOLUBILITY
BIOBIOPLATFORMSPLATFORMS
DRUGDRUGDELIVERYDELIVERY
DEVICESDEVICESEXCIPIENTSEXCIPIENTS FORMULATIONFORMULATIONDEVELOPMENTDEVELOPMENT
CONTRACTCONTRACTSERVICESSERVICES
Evonik Expands North American ContractEvonik Expands North American ContractDevelopment & ManufacturingDevelopment & ManufacturingCapabilities for Advanced InjectablesCapabilities for Advanced Injectables Evonik recently announced a €35 million expansion ofEvonik recently announced a €35 million expansion ofits contract development and manufacturing (CDMO)its contract development and manufacturing (CDMO)capabilities in North America to meet growing demandcapabilities in North America to meet growing demandfor controlled release injectable formulations. Thefor controlled release injectable formulations. Theexpansion of the U.S. and Canadian facilities, whichexpansion of the U.S. and Canadian facilities, whichincludes the installation of a new �lling line, productionincludes the installation of a new �lling line, productionfacilities and analytical labs, will create more than 50facilities and analytical labs, will create more than 50jobs.jobs.
“Evonik is a global strategic partner to pharmaceutical“Evonik is a global strategic partner to pharmaceuticalcompanies seeking enabling solutions for polymer andcompanies seeking enabling solutions for polymer andliposome-based dosage forms,” said Don Enns, Globalliposome-based dosage forms,” said Don Enns, GlobalHead of Drug Delivery for the Evonik Health CareHead of Drug Delivery for the Evonik Health CareBusiness Line. “By increasing the production capacity ofBusiness Line. “By increasing the production capacity ofour RESOMERour RESOMER functional excipients and expanding our functional excipients and expanding ourcontract development and production services, we cancontract development and production services, we canfurther help customers transform their APIs into high-further help customers transform their APIs into high-performance parenteral medicines.”performance parenteral medicines.”
Expansion of Evonik Birmingham LaboratoriesExpansion of Evonik Birmingham Laboratories
Evonik Birmingham Laboratories (BHM) in the U.S. StateEvonik Birmingham Laboratories (BHM) in the U.S. Stateof Alabama is a global centre of excellence forof Alabama is a global centre of excellence forbiomaterials and polymer-based injectable dosagebiomaterials and polymer-based injectable dosageforms.forms.
Contract Services,Contract Services, Exclusive Online Content,Exclusive Online Content, Formulation DevelopmentFormulation Development
®®
To further expand its range of parenteral drugTo further expand its range of parenteral drugdevelopment and manufacturing services, Evonik hasdevelopment and manufacturing services, Evonik hasinstalled an automated, custom-designed �lling line forinstalled an automated, custom-designed �lling line forcomplex injectable products. Supplied by Bausch +complex injectable products. Supplied by Bausch +Stroebel and scheduled to be fully operational later thisStroebel and scheduled to be fully operational later thisyear, the modular VarioSys® line will support the liquid,year, the modular VarioSys® line will support the liquid,lyophilized or powder-�lling of drugs in vial sizes of uplyophilized or powder-�lling of drugs in vial sizes of upto 50mL to be used in clinical or commercialto 50mL to be used in clinical or commercialapplications.applications.
Evonik is also constructing a new 2,900 square metreEvonik is also constructing a new 2,900 square metrebuilding at its BHM site that will signi�cantly expand thebuilding at its BHM site that will signi�cantly expand theglobal production capacity of its RESOMERglobal production capacity of its RESOMER portfolio of portfolio ofbioresorbable polymers. The new building, which isbioresorbable polymers. The new building, which isscheduled to be commissioned later this year, willscheduled to be commissioned later this year, willstrengthen Evonik’s technological and supply leadershipstrengthen Evonik’s technological and supply leadershipfor bioresorbable polymers and provide customers withfor bioresorbable polymers and provide customers withadditional dual-source supply options.additional dual-source supply options.
Expansion of Evonik Vancouver LaboratoriesExpansion of Evonik Vancouver Laboratories
In 2016, Evonik acquired Transferra Nanosciences Inc.,In 2016, Evonik acquired Transferra Nanosciences Inc.,a CDMO specialising in the development of lipida CDMO specialising in the development of lipidnanoparticle-based parenteral drugs. It is now namednanoparticle-based parenteral drugs. It is now namedEvonik Vancouver Laboratories.Evonik Vancouver Laboratories.
To help meet growing demand for its advanced CDMOTo help meet growing demand for its advanced CDMOservices, Evonik is upgrading the existing facility andservices, Evonik is upgrading the existing facility andadding a second adjacent building that will more thanadding a second adjacent building that will more thandouble the total size of its Vancouver site to 4,300double the total size of its Vancouver site to 4,300square meters. The investments, which include thesquare meters. The investments, which include theupgrade of GMP manufacturing facilities and theupgrade of GMP manufacturing facilities and theexpansion of laboratories and scale-up services, willexpansion of laboratories and scale-up services, willsupport new and existing customer programs.support new and existing customer programs.
About EvonikAbout Evonik
Evonik is one of the world leaders in specialtyEvonik is one of the world leaders in specialtychemicals. The focus on more specialty businesses,chemicals. The focus on more specialty businesses,customer-orientated innovative prowess and a trustfulcustomer-orientated innovative prowess and a trustfuland performance-oriented corporate culture form theand performance-oriented corporate culture form theheart of Evonik’s corporate strategy. They are the leverheart of Evonik’s corporate strategy. They are the leverfor pro�table growth and a sustained increase in thefor pro�table growth and a sustained increase in thevalue of the company. Evonik bene�ts speci�cally fromvalue of the company. Evonik bene�ts speci�cally fromits customer proximity and leading market positions.its customer proximity and leading market positions.Evonik is active in over 100 countries around the worldEvonik is active in over 100 countries around the worldwith more than 36,000 employees. In �scal 2017, thewith more than 36,000 employees. In �scal 2017, theenterprise generated sales of €14.4 billion and anenterprise generated sales of €14.4 billion and anoperating pro�t (adjusted EBITDA) of €2.36 billion.operating pro�t (adjusted EBITDA) of €2.36 billion.
VIDEOVIDEOSPOTLIGHT SPOTLIGHT
COMPANYCOMPANYPROFILESPROFILES
INDUSTRY EVENTSINDUSTRY EVENTS
AAPSAAPS Nov 3-6, 2019, SanNov 3-6, 2019, SanAntonio, TXAntonio, TX
BIO 2019BIO 2019 June 3-6, 2019,June 3-6, 2019,Philadelphia, PAPhiladelphia, PA
BIO InternationalBIO InternationalConventionConvention(#BIO2019)(#BIO2019) June 3-6, 2019June 3-6, 2019 Philadelphia, PAPhiladelphia, PA
ControlledControlledRelease SocietyRelease SocietyMeetingMeeting July 21-24, 2019,July 21-24, 2019,Valencia, SpainValencia, Spain
CPhI WorldwideCPhI Worldwide November 5-7,November 5-7,2019, Frankfurt,2019, Frankfurt,GermanyGermany
Universe ofUniverse ofPre�lled SyringesPre�lled Syringes& Injection& InjectionDevicesDevices October 22-23,October 22-23,Gothenburg,Gothenburg,SwedenSweden
®®
AbbVieAbbVieContractContractManufacturingManufacturing
--
ABITECABITECCorporationCorporation
--
Ajinomoto Bio-Ajinomoto Bio-PharmaPharmaServicesServices
--
AlcamiAlcami--AscendiaAscendiaPharmaceuticalsPharmaceuticals
--
BASFBASFCorporationCorporation
--
BaxterBaxterBioPharmaBioPharmaSolutionsSolutions
--
BD Medical –BD Medical –PharmaceuticalPharmaceuticalSystemsSystems
--
BioDuroBioDuro--CambrexCambrex--Capsugel –Capsugel –LonzaLonza
--
Captisol, aCaptisol, aLigandLigandCompanyCompany
--
About Nutrition & CareAbout Nutrition & Care
The Nutrition & Care segment is led by Evonik NutritionThe Nutrition & Care segment is led by Evonik Nutrition& Care GmbH and contributes to ful�lling basic human& Care GmbH and contributes to ful�lling basic humanneeds. That includes applications for everydayneeds. That includes applications for everydayconsumer goods as well as animal nutrition and healthconsumer goods as well as animal nutrition and healthcare. This segment employed about 8,200 employees,care. This segment employed about 8,200 employees,and generated sales of around €4.5 billion in 2017.and generated sales of around €4.5 billion in 2017.
Total Page Views: 482Total Page Views: 482
CatalentCatalentPharmaPharmaSolutionsSolutions
--
CordenPharmaCordenPharmaInternationalInternational
--
CPhI NorthCPhI NorthAmericaAmerica
--
CredenceCredenceMedSystems,MedSystems,IncInc
--
Croda HealthCroda HealthCareCare
--
Drug DeliveryDrug DeliveryExpertsExperts
--
EG-GILEROEG-GILERO--EnableEnableInjectionsInjections
--
EvonikEvonikIndustries AGIndustries AG
--
ExeleadExelead--FrontageFrontage--GatewayGatewayAnalytical LLCAnalytical LLC
--
GattefosseGattefosse--HovioneHovione--JRF GlobalJRF Global--Lonza PharmaLonza Pharma& Biotech& Biotech
--
MetricsMetricsContractContractServicesServices
--
MilliporeSigmaMilliporeSigma--Mitsubishi GasMitsubishi GasChemicalChemicalCompany, Inc.Company, Inc.
--
NemeraNemera--NobleNoble--PCI PharmaPCI PharmaServicesServices
--
PfanstiehlPfanstiehl--P�zerP�zerCentreOneCentreOne
--
PharmaCirclePharmaCircle--PortalPortalInstrumentsInstruments
--
ProMedProMedPharma, LLCPharma, LLC
--
SGS LifeSGS LifeSciencesSciences
--
SGW PharmaSGW PharmaMarketingMarketing
--
SHL GroupSHL Group--SoncebozSonceboz--UPMUPMPharmaceuticalsPharmaceuticals
--
Vetter PharmaVetter PharmaInternationalInternational
--
WestWestPharmaceuticalPharmaceuticalServicesServices
--
MARKET SEGMENTSMARKET SEGMENTS CORPORATECORPORATE
SUBMISSIONSUBMISSIONGUIDELINESGUIDELINESABOUT USABOUT USBACK ISSUESBACK ISSUESMEDIA PLANNERMEDIA PLANNERCONTACTCONTACTFREE PRINTFREE PRINTSUBSCRIPTIONSUBSCRIPTION
DRUG DEVELOPMENT &DRUG DEVELOPMENT &DELIVERYDELIVERY
219 Changebridge Road219 Changebridge Road Montville, NJ 07045Montville, NJ 07045 Tel: (973) 299-1200Tel: (973) 299-1200
Fax: (973) 299-7937Fax: (973) 299-7937
Copyright © 2018 Drug Development & Delivery. All Rights Reserved. Copyright © 2018 Drug Development & Delivery. All Rights Reserved. Privacy PolicyPrivacy Policy / / Terms and ConditionsTerms and Conditions This material may not be published, broadcast, rewritten, or redistributed without This material may not be published, broadcast, rewritten, or redistributed without permissionpermission.. Web design and development by Web design and development by WalkerTekWalkerTek..
ANALYTICAL/TESTINGANALYTICAL/TESTINGBIOAVAILABILITYBIOAVAILABILITY& SOLUBILITY& SOLUBILITYBIO PLATFORMSBIO PLATFORMSDRUG DELIVERYDRUG DELIVERYDEVICESDEVICES
EXCIPIENTSEXCIPIENTSFORMULATIONFORMULATIONDEVELOPMENTDEVELOPMENTCONTRACTCONTRACTSERVICESSERVICES
